De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Here is a summary of the most commonly used DSIP dosing protocol based on available reports: Starting DSIP dose: 100mcg administered at night, preferably three hours before bedtime
[DOI] [PubMed] [Google Scholar] 69.Wang Y., Hekimi S
After being absorbed by NK cells and CD8+ T cells, NAA can inhibit the formation of immunological synapses in these cells, leading to immune evasiveness
Rhee SG, Yang KS, Kang SW, Woo HA, Chang TS
So, I think that sort of forms the foundation there